oral interleukin 17A modulator
favorable in vivo PK profile in multiple species
from a previous patent and SBDD
J. Med. Chem.
LEO Pharma Research & Early Development, Ballerup, DK
Compound 23
Context. “Compound 23” (LEO Pharma) is an oral IL-17A protein−protein interaction modulator being developed for psoriasis and other inflammatory diseases. Like most cytokines, the involvement of IL-17A in chronic…